Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
7.71
+0.52 (7.23%)
At close: Jun 25, 2025, 4:00 PM
5.12
-2.59 (-33.59%)
Pre-market: Jun 26, 2025, 7:06 AM EDT
Altimmune Revenue
Altimmune had revenue of $5.00K in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $20.00K, down -95.12% year-over-year. In the year 2024, Altimmune had annual revenue of $20.00K, down -95.31%.
Revenue (ttm)
$20.00K
Revenue Growth
-95.12%
P/S Ratio
31,266.74
Revenue / Employee
$339
Employees
59
Market Cap
625.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20.00K | -406.00K | -95.31% |
| Dec 31, 2023 | 426.00K | 494.00K | -726.47% |
| Dec 31, 2022 | -68.00K | -4.48M | -101.54% |
| Dec 31, 2021 | 4.41M | -3.78M | -46.12% |
| Dec 31, 2020 | 8.19M | 2.38M | 41.09% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
ALT News
- 11 hours ago - Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 - GlobeNewsWire
- 12 days ago - Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions - GlobeNewsWire
- 23 days ago - Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential - Seeking Alpha
- 27 days ago - Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity - Seeking Alpha
- 5 weeks ago - Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) - GlobeNewsWire
- 6 weeks ago - Altimmune to Participate at Two Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Altimmune, Inc. (ALT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Altimmune Announces First Quarter 2025 Financial Results and Business Update - GlobeNewsWire